JP6482533B2 - クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 - Google Patents

クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 Download PDF

Info

Publication number
JP6482533B2
JP6482533B2 JP2016514143A JP2016514143A JP6482533B2 JP 6482533 B2 JP6482533 B2 JP 6482533B2 JP 2016514143 A JP2016514143 A JP 2016514143A JP 2016514143 A JP2016514143 A JP 2016514143A JP 6482533 B2 JP6482533 B2 JP 6482533B2
Authority
JP
Japan
Prior art keywords
seq
subject
variants
tnfsf15
locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016514143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526875A5 (enExample
JP2016526875A (ja
Inventor
ダーモット ピー． マクガバーン，
ダーモット ピー． マクガバーン，
Original Assignee
セダーズ−シナイ メディカル センター
セダーズ−シナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セダーズ−シナイ メディカル センター, セダーズ−シナイ メディカル センター filed Critical セダーズ−シナイ メディカル センター
Publication of JP2016526875A publication Critical patent/JP2016526875A/ja
Publication of JP2016526875A5 publication Critical patent/JP2016526875A5/ja
Application granted granted Critical
Publication of JP6482533B2 publication Critical patent/JP6482533B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016514143A 2013-05-17 2014-05-16 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体 Active JP6482533B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17
US61/824,932 2013-05-17
PCT/US2014/038468 WO2014186750A2 (en) 2013-05-17 2014-05-16 Variants of tnfsf15 and dcr3 associated with crohn's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018124311A Division JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Publications (3)

Publication Number Publication Date
JP2016526875A JP2016526875A (ja) 2016-09-08
JP2016526875A5 JP2016526875A5 (enExample) 2017-06-15
JP6482533B2 true JP6482533B2 (ja) 2019-03-13

Family

ID=51899024

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016514143A Active JP6482533B2 (ja) 2013-05-17 2014-05-16 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018124311A Withdrawn JP2018148931A (ja) 2013-05-17 2018-06-29 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2020096798A Withdrawn JP2020127437A (ja) 2013-05-17 2020-06-03 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2022093628A Withdrawn JP2022111329A (ja) 2013-05-17 2022-06-09 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
JP2024213907A Pending JP2025023316A (ja) 2013-05-17 2024-12-06 クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体

Country Status (7)

Country Link
US (4) US20160090629A1 (enExample)
EP (3) EP2997165A4 (enExample)
JP (5) JP6482533B2 (enExample)
KR (4) KR20210107176A (enExample)
CN (1) CN105358713B (enExample)
ES (1) ES2894963T3 (enExample)
WO (1) WO2014186750A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
KR20210107176A (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
KR20230003433A (ko) * 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
CN121371183A (zh) * 2018-09-07 2026-01-23 费城儿童医院 用于淋巴系统病症的诊断和治疗的组合物和方法
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
CN122060049A (zh) * 2019-09-13 2026-05-19 协和麒麟株式会社 DcR3变体
IL302791A (en) * 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
HRP20150684T1 (hr) * 2008-02-19 2015-09-11 The Children's Hospital Of Philadelphia, Abramson Pediatric Research Center, Office of Technology Transfer Identifikacija specifiäśnih mjesta nastanka - genetski loci - upalne bolesti crijeva kod djece i postupci njihove uporabe u takvoj dijagnozi te njihovo lijeäśenje
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
NZ619527A (en) * 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
WO2012054532A1 (en) 2010-10-18 2012-04-26 Prometheus Laboratories Inc. Methods for determining anti-drug antibody isotypes
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
AU2012259312A1 (en) * 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
KR20210107176A (ko) 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法

Also Published As

Publication number Publication date
US12281359B2 (en) 2025-04-22
KR20250130857A (ko) 2025-09-02
WO2014186750A3 (en) 2015-01-08
US20160090629A1 (en) 2016-03-31
ES2894963T3 (es) 2022-02-16
EP3498867A1 (en) 2019-06-19
EP2997165A4 (en) 2017-03-08
CN105358713B (zh) 2020-02-28
CN105358713A (zh) 2016-02-24
JP2025023316A (ja) 2025-02-14
EP3498867B1 (en) 2021-09-29
EP3988673A3 (en) 2022-08-03
US20180230543A1 (en) 2018-08-16
KR20230093538A (ko) 2023-06-27
JP2022111329A (ja) 2022-07-29
EP2997165A2 (en) 2016-03-23
WO2014186750A2 (en) 2014-11-20
KR20160009582A (ko) 2016-01-26
JP2020127437A (ja) 2020-08-27
US20210371931A1 (en) 2021-12-02
JP2018148931A (ja) 2018-09-27
ES2894963T8 (es) 2022-02-24
US20250243548A1 (en) 2025-07-31
KR20210107176A (ko) 2021-08-31
EP3988673A2 (en) 2022-04-27
JP2016526875A (ja) 2016-09-08
KR102295125B1 (ko) 2021-08-31

Similar Documents

Publication Publication Date Title
JP2018148931A (ja) クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
Maltby et al. Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients
Vanita et al. A novel mutation in the DNA‐binding domain of MAF at 16q23. 1 associated with autosomal dominant “cerulean cataract” in an Indian family
KR20130130732A (ko) 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측
EP2158330A2 (en) Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
US20160096885A1 (en) Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
JP6689743B2 (ja) 抑うつ症状及び不安症状の少なくとも一方を有する患者におけるバソプレッシン受容体１ｂアンタゴニストに対する治療応答を予測する方法
Schapiro et al. Panel sequencing distinguishes monogenic forms of nephritis from nephrosis in children
AU2006220604A1 (en) Diagnostic and therapeutic target for macular degeneration
CN1681941A (zh) 基于ApoE基因型治疗痴呆的方法
Evans et al. Novel 25 kb deletion of MERTK causes retinitis pigmentosa with severe progression
Nasri et al. A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population
HK40072596A (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
JP7090604B2 (ja) びまん性大細胞型ｂ細胞リンパ腫の予後予測因子、及び予後予測方法
Davoudi et al. Molecular analysis of ABCA4 gene in an Iranian cohort with Stargardt disease
Davatchi et al. HLA-B51 IN BEHCETS DISEASE
Khan et al. GENETIC RISK VARIANTS ARE COMMON IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS FROM MINORITIZED BACKGROUNDS
JP2008534019A (ja) ヒトニーマンピックｃ１様１遺伝子（ｎｐｃ１ｌ１）多型及びその使用方法
EP3174999A1 (en) Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
Hoffman Modeling Macular Degeneration Using Quantitative Phenotypes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190212

R150 Certificate of patent or registration of utility model

Ref document number: 6482533

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250